ADS PHARMS LTD
Opportunity 73/100 (strong), bankability 75/100. High owner-dependency — earn-out structure likely required for clean transition. Share purchase looks the cleaner deal structure. Biggest value-creation lever: Broaden director team. Sole director creates succession risk and reduces buyer comfort. Appoint a second director or strong #2. Most likely exit: strategic trade sale (65/100).
Data confidence
Overall: high (80/100)Strong data coverage across all sections. AI outputs should be trusted with minimal caveats.
Solid opportunity signal. Worth a dedicated memo and management meeting.
Signals from accounts
Derived from iXBRL accounts · accounting standard not declaredKey financials
2 years extracted from filed iXBRL accountsHover to see exact values · click legend to toggle series
Financials
Extracted from Companies House accounts · accounting standard unknown| Metric | 2025-08-31 | 2024-08-31 |
|---|---|---|
| Total assets | £280.2k | £142.6k |
| Current assets | £326.2k | £153.1k |
| Net assets | £279.3k | £141.6k |
Amounts extracted automatically from iXBRL. Fields left blank were not reported or not mapped. Values in GBP unless stated.
1 signal detected in this company's narrative notes — going-concern language, audit opinion, contingent liabilities, related-party transactions.
Available from the Pro tier upwards.
See pricing →Recent activity
- • 1 accounts
Corporate timeline (14 events)Click to expand
- 2026-02-18📄accounts-with-accounts-type-micro-entityaccounts · AA
- 2025-01-21📄accounts-with-accounts-type-micro-entityaccounts · AA
- 2024-01-15📄accounts-with-accounts-type-micro-entityaccounts · AA
- 2023-01-26📄accounts-with-accounts-type-micro-entityaccounts · AA
- 2022-01-28📄accounts-with-accounts-type-micro-entityaccounts · AA
- 2021-01-21📄accounts-with-accounts-type-micro-entityaccounts · AA
- 2020-01-21📄accounts-with-accounts-type-micro-entityaccounts · AA
- 2018-11-06📄accounts-with-accounts-type-micro-entityaccounts · AA
- 2018-02-21📄accounts-with-accounts-type-micro-entityaccounts · AA
- 2017-01-20📄accounts-with-accounts-type-total-exemption-smallaccounts · AA
- 2015-09-08🏢Company incorporatedAs ADS PHARMS LTD
- 2015-09-08➕BHALODA, Adil Iqbal appointeddirector
- 2015-09-08📄change-account-reference-date-company-current-shortenedaccounts · AA01
- 2015-09-08📄incorporation-companyincorporation · NEWINC
Owner dependency
The business appears inseparable from the founder. Acquisition without a serious earn-out or meaningful transition period would likely destroy value.
- +Sole director: Only one active director — all governance concentrated on one person.
- +No director turnover: Company is 11 years old with no director changes — suggests a very tight-knit founder team never broadened.
Succession & seller-readiness
Some succession indicators present. Worth watching; approach if sector/strategy fits.
- primarySole active director: Only one director in control. No visible successor — buyers solve the succession problem.
- supportingClean filings + long tenure: Disciplined long-tenure operator — classic lifestyle-business pattern that often sells quietly.
Red flags
cleanShareholders & ownership
1 active beneficial owner · dominant holder ≥75%| Name | Shares | Voting rights | Nature of control | Notified |
|---|---|---|---|---|
Mr Adil Iqbal Bhaloda Individual · British · DOB 10/1989 · age 37 | 75–100% | — | 75-100% shares | 01/09/2016 |
From Companies House Persons with Significant Control filings. Share ranges are banded per the public PSC regime.
Radial SVG graph showing every company connected via shared directors, colour-coded by status.
Available from the Pro tier upwards.
See pricing →Similar companies
Active · Healthcare & medical · BL postcode area| Company | Est. value | Turnover | Net worth | Staff | Age | Opp | Director |
|---|---|---|---|---|---|---|---|
| A. FLETCHER LIMITED→ 04459941 · est 2002 · no financials extracted | — | — | — | — | 23y | — | — |
| ABZ EL TOURKY LIMITED→ 15820119 · est 2024 · no financials extracted | — | — | — | — | 1y | — | — |
| ADEBAYOR UK LIMITED→ 12011477 · est 2019 · no financials extracted | — | — | — | — | 6y | — | — |
| AFIRO UK LIMITED→ 06727718 · est 2008 · no financials extracted | — | — | — | — | 17y | — | — |
| AFZAL OPTICAL LIMITED→ 06778857 · est 2008 · no financials extracted | — | — | — | — | 17y | — | — |
| AGE WITH ELEGANCE MEDICAL AESTHETICS & SKIN CLINIC LTD→ 16453931 · est 2025 · no financials extracted | — | — | — | — | — | — | — |
| AHN MEDICAL SERVICES LTD→ 12399225 · est 2020 · no financials extracted | — | — | — | — | 6y | — | — |
| AIGBEHI LTD→ 13892612 · est 2022 · no financials extracted | — | — | — | — | 4y | — | — |
| AIMS THERAPY LTD→ 16000666 · est 2024 · no financials extracted | — | — | — | — | 1y | — | — |
| AJ PHARMA LIMITED→ 09179999 · est 2014 · no financials extracted | — | — | — | — | 11y | — | — |
| AJ SKIN & BODY CLINIC LTD→ 17084681 · est 2026 · no financials extracted | — | — | — | — | — | — | — |
| AJM PODIATRY LIMITED→ 09924211 · est 2015 · no financials extracted | — | — | — | — | 10y | — | — |
7 specific questions generated from this company's actual signals — liquidity, leverage, director age, charge count, red flags, age-of-company.
Available from the Pro tier upwards.
See pricing →Exit-route ranking, improvement thesis, quiet-distress detector, covenant-pressure proxy, extraction monitor, approaching triggers, ownership drift, local cluster, value trap, debt capacity, archetype classification — 48+ scoring modules.
Available from the Pro tier upwards.
See pricing →Company details
Registered office
Filing status
Officers (1 active · 0 resigned)
Click a director name to see their full track record across all companies.